Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...

NEW ORLEANS — Survodutide, an investigational glucagon receptor/GLP-1 receptor dual agonist, produced significant weight loss along with reductions in visceral fat and liver fat in two phase 3 trials.

Object storage has quietly become the default backend for half the data infrastructure being built today, and almost nobody outside the engineering teams notices. I sat ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

Boehringer Ingelheim disclosed full Phase 3 data for survodutide at the American Diabetes Association's 2026 Scientific Sessions in New Orleans on Sunday, June 7, showing that nearly 1 in 5 patients ...

As of October 2025, the World Economic Outlook database and supporting documents will be accessible through the IMF Data portal. The World Economic Outlook (WEO) database is created during the ...

Users, who play heavy games and use graphic content on their PC might have come across VSync (Vertical Sync) on their Nvidia or AMD Radeon settings. Learn how to disable VSync or Vertical Sync in ...